| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| AEON Biopharma Inc. Class A | ABP-450 (prabotulinumtoxinA) | Cervical dystonia | Phase 3 | Trial Planned | Intramuscular | Neurology |
| AEON Biopharma Inc. Class A | ABP-450 (prabotulinumtoxinA) | Chronic Migraine (prophylaxis) | Phase 3 | Trial Discontinued | Intramuscular | Neurology |
| Affimed N.V. | Acimtamig (AFM13) - (REDIRECT) | CD30-positive peripheral T cell lymphoma (PTCL) | Phase 2 | Intravenous | Oncology | |
| Affimed N.V. | AFM13 with AlloNK - (LuminICE-203) | Hodgkin Lymphoma | Phase 2 | Ongoing | Intravenous | Oncology |
| Affimed N.V. | AFM13 + AlloNK (AB-101) - (LuminICE-203) | Classical Hodgkin Lymphoma (cHL), relapsed/refractory CD30-positive lymphoma | Phase 2 | Data Released | Intravenous | Oncology |
| Affimed N.V. | Acimtamig (AFM13) - (REDIRECT) | CD30-positive peripheral T cell lymphoma (PTCL) | Phase 2 | Intravenous | Oncology | |
| Affimed N.V. | AFM13 + AlloNK (AB-101) - (LuminICE-203) | Classical Hodgkin Lymphoma (cHL), relapsed/refractory CD30-positive lymphoma | Phase 2 | Data Released | Intravenous | Oncology |
| Agenus Inc. | Botensilimab - (ACTIVATE) | Advanced MSS Colorectal Cancer and Advanced Melanoma | BLA Filing | Data Released | Intravenous | Oncology |